- Mineral, Bone & Muscle
- Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
-
Wei Lin Tay, Donovan Tay
-
Endocrinol Metab. 2022;37(2):183-194. Published online April 14, 2022
-
DOI: https://doi.org/10.3803/EnM.2021.1369
-
-
26,485
View
-
1,177
Download
-
12
Web of Science
-
15
Crossref
-
 Abstract
 PDF PubReader  ePub
- Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL), involved in bone resorption. Continued use of denosumab results in a potent and sustained decrease in bone turnover, an increase in bone mineral density (BMD), and a reduction in vertebral and hip fractures. The anti-resorptive effects of denosumab are reversible upon cessation, and this reversal is accompanied by a transient marked increase in bone turnover that is associated with bone loss, and of concern, an increased risk of multiple vertebral fractures. In this review, we outline the effects of denosumab withdrawal on bone turnover markers, BMD, histomorphometry, and fracture risk. We provide an update on recent clinical trials that sought to answer how clinicians can transition away from denosumab safely with follow-on therapy to mitigate bone loss and summarise the recommendations of various international guidelines.
-
Citations
Citations to this article as recorded by  - Multiple vertebral fractures after antiosteoporotic medications discontinuation: A comparative study to evaluate the potential rebound effect of denosumab
Mar Martín-Pérez, Beatriz Sánchez-Delgado, Patricia García-Poza, Sergio López-Álvarez, Elisa Martín-Merino
Bone.2025; 190: 117325. CrossRef - Naïve Bayes is an interpretable and predictive machine learning algorithm in predicting osteoporotic hip fracture in-hospital mortality compared to other machine learning algorithms
Jo-Wai Douglas Wang, Mathew V. Kiang
PLOS Digital Health.2025; 4(1): e0000529. CrossRef - Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes
Carmelinda Ruggiero, Carla Caffarelli, Valeria Calsolaro, Laura Tafaro, Francesca Riuzzi, Valentina Bubba, Nicola Napoli, Marika Ferracci, Patrizia Mecocci, Andrea Giusti, Giuseppe Rinonapoli
Drugs & Aging.2025; 42(1): 21. CrossRef - Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use
Jeonghoon Ha, Youn-Ju Lee, Jinyoung Kim, Chaiho Jeong, Yejee Lim, Jeongmin Lee, Ki-Hyun Baek
Endocrinology and Metabolism.2025; 40(1): 47. CrossRef - Disorders of bone and mineral metabolism in pregnancy and lactation: A case based clinical review
Manju Chandran, Sarah Ying Tse Tan
Osteoporosis and Sarcopenia.2025; 11(1): 1. CrossRef - Axillaridine A suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss
via inhibition of RANKL-mediated RANK signaling pathways
Jin Li, Jing Xu, Zhe Jiang, Meiyan Duan, Yingqi Yin, Zemin Xiang, Xuanjun Wang, Jun Sheng, Titi Liu, Huanhuan Xu
Food Science and Human Wellness.2025; 14(6): 9250397. CrossRef - Denosumab: A Useful Addition to the Armamentarium for the Management of Male Osteoporosis
Jijith Krishnan, Sham Santhanam, Bhuwan Singh, Salim Patel, Divya G Bhojwani, Sameer Muchhala
Cureus.2024;[Epub] CrossRef - Enhancing Treatment Success in Osteoporosis: Optimising the Use of Teriparatide
European Medical Journal.2024; : 49. CrossRef - Denosumab combined with chemotherapy followed by anlotinib in the treatment of multiple metastases of malignant peripheral nerve sheath tumor: a case report and literature review
Qian Chen, Haocheng Cui, Kai Zheng, Ming Xu, Xiuchun Yu
Frontiers in Oncology.2024;[Epub] CrossRef - The use of denosumab in osteoporosis – an update on efficacy and drug safety
Dima L. Diab, Nelson B. Watts
Expert Opinion on Drug Safety.2024; 23(9): 1069. CrossRef - Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years
Jeongmin Lee, Youn-Ju Lee, Jeonghoon Ha
Journal of Bone Metabolism.2024; 31(3): 246. CrossRef - Osteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024)
Hans Peter Dimai, Christian Muschitz, Karin Amrein, Rosemarie Bauer, Daniel Cejka, Rudolf Wolfgang Gasser, Reinhard Gruber, Judith Haschka, Timothy Hasenöhrl, Franz Kainberger, Katharina Kerschan-Schindl, Roland Kocijan, Jürgen König, Norbert Kroißenbrunn
Wiener klinische Wochenschrift.2024; 136(S16): 599. CrossRef - Denosumab stimulates spermatogenesis in infertile men with preserved Sertoli cell capacity
Christine H. Andreassen, Rune Holt, Li Juel Mortensen, Nadia Krarup Knudsen, John E. Nielsen, Nadia Nicholine Poulsen, Sam K. Yahyavi, Ida M. Boisen, Zhihui Cui, Luisina Ongaro, Jasmin P. Hjerresen, Birgitte G. Toft, Thomas Hasselager, Niklas R. Jørgensen
Cell Reports Medicine.2024; 5(10): 101783. CrossRef - Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury
Christopher M. Cirnigliaro, Michael F. La Fountaine, J. Scott Parrott, Steven C. Kirshblum, Susan J. Sauer, Sue A. Shapses, Isa A. McClure, William A. Bauman
Osteoporosis International.2023; 34(4): 741. CrossRef - Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
Chaiho Jeong, Jeongmin Lee, Jinyoung Kim, Jeonghoon Ha, Kwanhoon Jo, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Tae-Seo Sohn, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek
Endocrinology and Metabolism.2023; 38(2): 260. CrossRef
|
KES
